In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1932 News Items found
MSK Medical oncologist and liver cancer specialist Dr. Ghassan K. Abou-Alfa
Article
Liver Cancer Progression Slowed by Adding Immunotherapy to TACE

Read about a new treatment that slows the progression of intermediate-risk liver cancer.
Dr. Alexander Drilon
Targeted Drug Selpercatinib Greatly Reduces Risk of Recurrence in Early-Stage Lung Cancer

A clinical trial led by an MSK researcher found that the targeted therapy selpercatinib reduces the risk of recurrence by more than 80% for patients with early-stage non-small cell lung cancers carrying a RET gene fusion.
Andi Straus and her son, Nadav, pose on a hiking trail.
Targeted Therapy Shows Promising Results Against Rare Soft Tissue Sarcoma

A clinical trial led by doctors from MSK has found that abemaciclib — a drug already approved for certain breast cancers — can significantly slow the growth of dedifferentiated liposarcoma, a rare, aggressive soft tissue cancer.
An MSK researcher at work in the lab
MSK Research Highlights, May 26, 2026

New MSK research provides structural insights into how cancer cells thwart targeted RAS therapies; uncovers promising combination therapies for a rare childhood brain tumor; uses organoids to provide important clues about what drives pancreatic cancer; takes aim at appendix cancer with new laboratory models; and a develops a new precision tool for targeting cancer's energy factory.
Dr. Shanu Modi speaks with a patient
In the Clinic
FDA Approves Trastuzumab Deruxtecan (T-DXd) for Early-Stage HER2-Positive Breast Cancer

The FDA has approved trastuzumab deruxtecan (T-DXd, Enhertu) for treating early-stage, HER2-positive breast cancer based in part on clinical research led by MSK breast medical oncologist Shanu Modi, MD.
Riders on stationary bikes cheer and hold pompoms in a party-like atmosphere for Cycle for Survival
MSK Giving in 2025

In 2025, the MSK Giving community accelerated its commitment to redefine what’s possible in cancer care worldwide. Together, 348,000 donors contributed...
GSK Graduates and MSK Leadership pose on the stage
MSK’s 2026 Graduation Recognizes Today's Achievements and Tomorrow's Leaders

At Memorial Sloan Kettering Cancer Center’s 47th annual ceremony, graduating master's and PhD students were honored and award winners were recognized.
A doctor holds the hand of a patient, who is dressed in a hospital gown
Just Diagnosed With a Brain Tumor? What You Should Do Next

Learn what to do right after you've been diagnosed with brain cancer, from MSK experts who specialize in treating this kind of cancer.
micrograph of a T cell
Successfully Treated AML Patients May Hold the Key to New CAR T Cell Therapy

A team of researchers from MSK has developed a new type of CAR T cell therapy that shows promise against acute myeloid leukemia (AML) in preclinical models.
A hand points to brain images on a screen.
In the Clinic
Treating Cancer When It Spreads to the Brain

MSK doctors and scientists are leading the charge to find new and innovative ways to treat metastatic brain cancer.